Kumar Katakam S, Tria V, Sim WC, Yip GW, Molgora S, Karnavas T, Elghonaimy EA, Pelucchi P, Piscitelli E, Ibrahim SA, Zucchi I, Reinbold R, Greve B, Götte M.
Forschungsartikel (Zeitschrift) | Peer reviewedIn colon cancer, downregulation of the transmembrane heparan sulfate proteoglycan syndecan-1 (Sdc-1) is associated with increased invasiveness, metastasis, and dedifferentiation. As Sdc-1 modulates signaling pathways relevant to stem cell function, we tested the hypothesis that it may regulate a tumor-initiating cell phenotype. Sdc-1 small-interfering RNA knockdown in the human colon cancer cell lines Caco2 and HT-29 resulted in an increased side population (SP), enhanced aldehyde dehydrogenase 1 activity, and higher expression of CD133, LGR5, EPCAM, NANOG, SRY (sex-determining region Y)-box 2, KLF2, and TCF4/TCF7L2. Sdc-1 knockdown enhanced sphere formation, cell viability, Matrigel invasiveness, and epithelial-to-mesenchymal transition-related gene expression. Sdc-1-depleted HT-29 xenograft growth was increased compared to controls. Decreased Sdc-1 expression was associated with an increased activation of β1-integrins, focal adhesion kinase (FAK), and wingless-type (Wnt) signaling. Pharmacological FAK and Wnt inhibition blocked the enhanced stem cell phenotype and invasive growth. Sequential flow cytometric SP enrichment substantially enhanced the stem cell phenotype of Sdc-1-depleted cells, which showed increased resistance to doxorubicin chemotherapy and irradiation. In conclusion, Sdc-1 depletion cooperatively enhances activation of integrins and FAK, which then generates signals for increased invasiveness and cancer stem cell properties. Our findings may provide a novel concept to target a stemness-associated signaling axis as a therapeutic strategy to reduce metastatic spread and cancer recurrence.
Götte, Martin | Klinik für Frauenheilkunde und Geburtshilfe |
Greve, Burkhard | Klinik für Strahlentherapie - Radioonkologie - |
Laufzeit: 01.07.2015 - 30.06.2019 Gefördert durch: EU H2020 - Marie Skłodowska-Curie Actions - Research and Innovation Staff Exchange Art des Projekts: EU-Projekt koordiniert an der Universität Münster | |
Laufzeit: 01.01.2010 - 31.12.2012 Gefördert durch: Deutsch-Israelische Stiftung für Wissenschaftliche Forschung und Entwicklung Art des Projekts: Gefördertes Einzelprojekt | |
Laufzeit: 10.03.2009 - 31.03.2014 | 1. Förderperiode Gefördert durch: DFG - Internationales Graduiertenkolleg Art des Projekts: DFG-Hauptprojekt koordiniert an der Universität Münster |
Syndecan-1 and heparanase as novel regulators of colon cancer stem cell function Promovend*in: Kumar Katakam, Sampath | Betreuer*innen: Götte, Martin; Moerschbacher, Bruno; Greve, Burkhard Zeitraum: 01.09.2011 - 01.04.2015 Promotionsverfahren erfolgt(e) an: Promotionsverfahren an der Universität Münster |